Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
How many years of EBITDA are required to pay off the company's net debt considering the lease agreements, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
It shows the Lease percentage that is impacting the total amount of the company's debt.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!